Matches in SemOpenAlex for { <https://semopenalex.org/work/W2623590902> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2623590902 abstract "1046 Background: The combination of endocrine therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor, such as palbociclib, has changed the treatment paradigm of HR+ MBC, particularly as 1 st line therapy. However, there are no predictive biomarkers at present, and little is known about the impact of tumor genomics on outcomes. For example, mutations in TP53 could impact the ability of p53 to negatively regulate p21, thereby promoting cell cycle progression despite CDK 4/6 inhibition. The aim of this study was to evaluate the association between tumor genomics, particularly PIK3CA and TP53 mutations, and response to CDK 4/6 inhibitors in HR+ MBC. Methods: All HR+/HER2- MBC patients at our institution receiving a CDK 4/6 inhibitor in the second line or beyond were identified. Tumor genomics were analyzed utilizing the institutional tumor genotyping next generation sequencing (NGS) assay known as “Snapshot-NGS assay” on DNA isolated from the tumor, covering key oncogenic driver mutations and tumor suppressor genes. The log-rank test was used for statistical analysis. Results: A total of 83 patients with HR+/HER2- MBC were identified, of which 61 had available tumor genotyping results available (52 metastatic specimens). The median line of therapy was three. Median progression-free survival (PFS) on CDK 4/6 inhibitor-based therapy, as second line or beyond, was 9.2 months (mo) overall. No significant difference in PFS was seen among patients with PIK3CA (n = 31) mutations (7.1 vs. 9.7 mo; p = 0.28) or with any alteration in the PI3K/Akt/mTOR (n = 36) pathway (8.2 vs. 9.3 mo; p = 0.40). The presence of a p53 mutation (n = 9) or complex tumor genomics (n = 14) demonstrated a trend towards shorter PFS (5.5 vs. 9.2 mo; 5.5 vs. 9.5 mo, respectively), although statistical significance was not reached due to small numbers (p = 0.76; p = 0.31). In a multivariable analysis adjusting for age and prior lines of therapy, similar results were observed. Conclusions: This study suggests patients with HR+ MBC harboring p53 mutations or complex tumor genomics may experience shorter PFS on CDK 4/6 inhibitor-based therapy in the second line and beyond, and these novel findings require validation in additional studies." @default.
- W2623590902 created "2017-06-15" @default.
- W2623590902 creator A5003417891 @default.
- W2623590902 creator A5006018613 @default.
- W2623590902 creator A5007607833 @default.
- W2623590902 creator A5017550097 @default.
- W2623590902 creator A5018738915 @default.
- W2623590902 creator A5028403057 @default.
- W2623590902 creator A5034972183 @default.
- W2623590902 creator A5052735318 @default.
- W2623590902 creator A5056275493 @default.
- W2623590902 creator A5084390948 @default.
- W2623590902 creator A5087308492 @default.
- W2623590902 date "2017-05-20" @default.
- W2623590902 modified "2023-09-26" @default.
- W2623590902 title "Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)." @default.
- W2623590902 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.1046" @default.
- W2623590902 hasPublicationYear "2017" @default.
- W2623590902 type Work @default.
- W2623590902 sameAs 2623590902 @default.
- W2623590902 citedByCount "3" @default.
- W2623590902 countsByYear W26235909022018 @default.
- W2623590902 crossrefType "journal-article" @default.
- W2623590902 hasAuthorship W2623590902A5003417891 @default.
- W2623590902 hasAuthorship W2623590902A5006018613 @default.
- W2623590902 hasAuthorship W2623590902A5007607833 @default.
- W2623590902 hasAuthorship W2623590902A5017550097 @default.
- W2623590902 hasAuthorship W2623590902A5018738915 @default.
- W2623590902 hasAuthorship W2623590902A5028403057 @default.
- W2623590902 hasAuthorship W2623590902A5034972183 @default.
- W2623590902 hasAuthorship W2623590902A5052735318 @default.
- W2623590902 hasAuthorship W2623590902A5056275493 @default.
- W2623590902 hasAuthorship W2623590902A5084390948 @default.
- W2623590902 hasAuthorship W2623590902A5087308492 @default.
- W2623590902 hasConcept C121608353 @default.
- W2623590902 hasConcept C126322002 @default.
- W2623590902 hasConcept C143998085 @default.
- W2623590902 hasConcept C170493617 @default.
- W2623590902 hasConcept C23589133 @default.
- W2623590902 hasConcept C2775930923 @default.
- W2623590902 hasConcept C2779744173 @default.
- W2623590902 hasConcept C502942594 @default.
- W2623590902 hasConcept C530470458 @default.
- W2623590902 hasConcept C71315377 @default.
- W2623590902 hasConcept C71924100 @default.
- W2623590902 hasConceptScore W2623590902C121608353 @default.
- W2623590902 hasConceptScore W2623590902C126322002 @default.
- W2623590902 hasConceptScore W2623590902C143998085 @default.
- W2623590902 hasConceptScore W2623590902C170493617 @default.
- W2623590902 hasConceptScore W2623590902C23589133 @default.
- W2623590902 hasConceptScore W2623590902C2775930923 @default.
- W2623590902 hasConceptScore W2623590902C2779744173 @default.
- W2623590902 hasConceptScore W2623590902C502942594 @default.
- W2623590902 hasConceptScore W2623590902C530470458 @default.
- W2623590902 hasConceptScore W2623590902C71315377 @default.
- W2623590902 hasConceptScore W2623590902C71924100 @default.
- W2623590902 hasLocation W26235909021 @default.
- W2623590902 hasOpenAccess W2623590902 @default.
- W2623590902 hasPrimaryLocation W26235909021 @default.
- W2623590902 hasRelatedWork W2065392523 @default.
- W2623590902 hasRelatedWork W2774196372 @default.
- W2623590902 hasRelatedWork W2889802486 @default.
- W2623590902 hasRelatedWork W2937576470 @default.
- W2623590902 hasRelatedWork W2947245065 @default.
- W2623590902 hasRelatedWork W2947950759 @default.
- W2623590902 hasRelatedWork W3024894103 @default.
- W2623590902 hasRelatedWork W3028787438 @default.
- W2623590902 hasRelatedWork W3031150423 @default.
- W2623590902 hasRelatedWork W3032348824 @default.
- W2623590902 hasRelatedWork W3032549624 @default.
- W2623590902 hasRelatedWork W3032729839 @default.
- W2623590902 hasRelatedWork W3032762552 @default.
- W2623590902 hasRelatedWork W3100453868 @default.
- W2623590902 hasRelatedWork W3111417899 @default.
- W2623590902 hasRelatedWork W3166020022 @default.
- W2623590902 hasRelatedWork W3172525964 @default.
- W2623590902 hasRelatedWork W3172822437 @default.
- W2623590902 hasRelatedWork W3189331974 @default.
- W2623590902 hasRelatedWork W3195802133 @default.
- W2623590902 isParatext "false" @default.
- W2623590902 isRetracted "false" @default.
- W2623590902 magId "2623590902" @default.
- W2623590902 workType "article" @default.